Associate Director Of Market Development
• Led Scientific and Regulatory Affairs for the Mutagenesis (drug safety) business unit.• Developed and launched a global regulatory approval strategy, securing US and UK support.• Oversaw evidence generation resulting in 25+ peer-reviewed publications.• Organized a UK workshop leading to $1M in new revenue and key partnerships.• Managed market development, KOL engagement, and the conference/society strategy. • Served as subject matter expert in error-corrected Next Generation Sequencing (ecNGS) assays, applications and experimental design across areas, including: mutagenesis, carcinogenesis, off-target genome editing, cell therapy, gene therapy, chimerism tracking, acute myeloid leukemia minimal residual disease (AML MRD) testing, and patient-specific (aka 'tumor-informed') MRD.